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1.1. Mucopolysaccharidosis and glycosaminoglycans (GAGs)
The word mucopolysaccharidosis (MPS) literally means “a disease
in which viscous polysaccharides are being stored”. There are eleven
such diseases, each caused by genetic deﬁciency of a different
lysosomal enzyme involved in the degradation of these polysaccha-
rides. The diseases are numbered from MPS I to MPS IX and named
after the physicians who ﬁrst described the syndromes or discovered
the underlying enzyme deﬁciency (Table 1) [1–9].Chemically, the viscous polysaccharides are glycosaminoglycans
(GAGs) that consist of long, un-branched chains of negatively charged
amino sugars and uronic acids and have a very high capacity to bind
water. Most are linked to a protein core (proteoglycan), form large
complexes with hyaluronic acid, and are the ground substance of
connective tissues. Depending on the precise composition of the
polysaccharide chain, the glycosaminoglycans have names such as
dermatan sulfate, heparan sulfate, keratan sulfate, chondroitin sulfate
and hyaluronic acid (Table 1).
Connective tissue is composed of cells and extracellular matrix
(ECM). Thematrix is produced by the cells and consists of protein ﬁbers
(mainly collagen) and proteoglycans. It provides volume and function,
which is speciﬁed largely by its chemical composition. For instance, the
connective tissue located directly under the epithelium of the skin and
under the endotheliumof the large blood vessels is loosely organized so
as to provide a soft cushion that can absorb subtle transformation by
pressure. In non-structural organs such as the liver, the connective
tissue literally holds the hepatocytes together in a functional network of
cell strains and blood sinuses. Articular cartilage (joints) is very rich in
GAGs and can contain up to 80% of water. The jelly-like substance is
optimally structured to absorb pressure, but breaks up when traction is
applied. It is thusunlike tendons,whoseglycosaminoglycan content and
cell density are low, but whose collagen content is high, the collagen
ﬁbers also being laid in a single direction to transduce force. The
connective tissue matrix of bone and teeth is mineralized. GAGs also
serve as key biological response modiﬁers [10–12].
Like any other biological substance in the body, GAGs are continuously
renewed. They are degraded by enzymes produced by the connective
tissue cells; in part extracellularly and in part intracellularly in the
Table 1
Enzyme deﬁciencies and storage products in MPS.
Number Eponym Enzyme deﬁciency Storage product
I Hurler/
Scheie
α-L-iduronidase Heparan sulfate/dermatan
sulfate
II Hunter Iduronate 2-sulfatase Heparan sulfate/dermatan
sulfate
III-A Sanﬁlippo
type A
Sulfamidase Heparan sulfate
III-B Sanﬁlippo
type B
α-N-
acetylglucosaminidase
Heparan sulfate
III-C Sanﬁlippo
type C
Acetyl-CoA; α
glucosaminide
N-acetyltransferase
Heparan sulfate
III-D Sanﬁlippo
type D
N-acetylglucosamine
6-sulfatase
Heparan sulfate
IV-A Morquio
type A
Galactose 6-sulfatase Keratan sulfate/chondroitin
6-sulfate
IV-B Morquio
type B
β-galactosidase Keratan sulfate/chondroitin
6-sulfate
VI Maroteaux–
Lamy
N-acetylgalactosamine
4-sulfatase
Dermatan sulfate/chondroitin
4-sulfate
VII Sly β-glucuronidase Heparan sulfate/dermatan
sulfate/chondroitin
4-sulfate/chondroitin
6-sulfate
IX Hyaluronidase Hyaluronic acid
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lysosomal enzyme deﬁciency leads to intralysosomal GAG storage,
followed by loss of cellular functions, tissue damage and organ
dysfunction. This process determines the clinical symptoms observed in
patients with mucopolysaccharidoses.
This reviewdescribes theprocesses underlyingnormal development
of bone, joints and teeth in relation to abnormalities seen in MPS
patients and MPS animal models and the therapeutic challenges these
abnormalities present.
1.2. Bones, joints and teeth in MPS patients
As well as joint and dental problems, most patients with mucopo-
lysaccharidoses have bone problems that cause skeletal deformities.
Someof these clinical features are illustrated in Fig. 1. The bone and joint
abnormalities were summarized recently [13].
Due mainly to lysosomal deposition of GAGs in the chondrocytes
[14], the extracellular matrix (ECM) of the articular cartilage, the
synovia, and the surrounding tissues, MPS patients have stiff joints,
contractures and poor mobility. Hyperlaxity of the joints can also occur.
Together, these processes ultimately manifest as degenerative joint
disease. Since the abnormalities develop early in life, they also interfere
with normal growth, which explains the typical short stature of most
MPS patients (Fig. 2).
Before we introduce the pathophysiology of MPSs, the following
paragraphs describe the normal development of bones, joints and
teeth ﬁrst.
2. Normal development of bones, joints and teeth
2.1. Bones
The human skeleton consists of bones that meet at joints and are
held together by ligaments. To enable movement, tendons connect
bones withmuscles. Cartilage is part of the skeleton. It is found in joints
and in the growth plate of immature long bones. The skeleton also
serves as a scaffold and cage that supports and protects vital organs.
Bone tissue is a reservoir for calcium, phosphate and other ions, and
harbors themarrow, which is essential for blood-cell formation. Bone is
maintained by osteocytes, each of which is directly connected with the
circulation by thin cytoplasmic extensions running to the blood vesselsthrough canaliculi (small tunnels in the calciﬁed bonematrix). Together
with osteoclasts, osteoblasts are instrumental in bone synthesis and
bone remodeling. In a process called endochondral ossiﬁcation, long
bones growdue to the proliferation and differentiation of chondroblasts
in the growth plate of immature long bones; newly formed cartilage is
replaced by bone as fast as it is formed. Flat bones are formed by the
differentiation of mesenchymal cells to bone-forming osteoblasts in a
process known as intramembranous ossiﬁcation.
Three types of cell are important for the formation, growth, renewal
andmaintenance of bone: osteoblasts, osteocytes and osteoclasts. Their
roles and functions are detailed below.
Osteoblasts, the bone-forming cells, are of mesodermal origin.
Originating from multipotent mesenchymal cells, they differentiate
into osteocytes while synthesizing the organic components of the bone
matrix (type I collagen, proteoglycans, and glycoproteins). The young
bone is deposited along the remnants of the cartilage of the growthplate
and alongpre-existing boneasanosteoid layer that turns into boneafter
calciﬁcation.
The lifespan of an osteoblast ranges from one to two hundred days.
Sixty to eighty percent dies by apoptosis [15].
Osteocytes, the cells surrounded by calciﬁed bone, have a very long
lifespan of one to ﬁfty years. Maintaining the bones throughout the
skeleton, they are about ten timesmore numerous than the osteoblasts,
and a thousand times more numerous than the osteoclasts [15,16].
Housing in lacunae between lamellae of matrix, they maintain contact
with each other and with cells at the bone surface through long, very
thin dendritic processes that traverse the bone matrix [15]. A gel-like
matrix surrounds the osteocytes and the dendritic processes. Through
the canaliculi, oxygen, nutrients and waste products are transported to
and from the osteocytes by hydraulic vascular pressure, partly by
diffusion and partly by the convection induced by mechanical forces.
Osteoclasts are created by the fusion and differentiation of cells from
the monocyte-macrophage cell lineage; they contain between ﬁve and
ﬁfty nuclei [17]. The lifespan of an osteoclast is approximately one to
twenty-ﬁve days, and they die by apoptosis [15].
Osteoclasts are bone-resorptive cells that play a crucial role in
normal bone turnover. They adhere tightly to the bone surface, where
they create an extracellular lysosomal space [18], in which protons are
secreted by the vacuolar H+-ATPase pump [19,20]. The apical
membrane of the polarized osteoclast opposing the bone is rufﬂed;
into this membrane, lysosomal vesicles are inserted [21]. The bone
minerals dissolve in the acidic environment of the extracellular space,
paving the way for lysosomal proteases to degrade the organic
components of the bone matrix [20,21]. The degradation products are
endocytosed at the rufﬂed bordermembrane and delivered to the basal
membrane by transcytosis [22,23].
2.2. Bone formation and remodeling
As stated brieﬂy in the Introduction, there are two ways in which
bones are formed. Both processes involve the transformation of pre-
existing mesenchymal tissue into bone tissue. In the process of
intramembranous or desmal ossiﬁcation, mesenchymal cells directly
differentiate into osteoblasts that produce the bone matrix, which
subsequently acquires its strength through mineralization. By contrast,
endochondral ossiﬁcation involves the primary deposit of a cartilage
template, which originates throughmesenchymal cell differentiation and
is gradually replaced by bone.
The growth of short bones and ﬂat bones is achieved by
intramembranous ossiﬁcation. Compacted mesenchymal cells deﬁne
an ossiﬁcation center, which is surrounded by the periosteum, a thin
layer of connective tissuewith osteoprogenitor cells at the bone surface
side and ﬁbrogenic cells adjacent to the mesenchyme. The osteogenic
cells differentiate into osteoblasts and continuously deposit new layers
of lamellar bone against the preexisting bone [16,24]. The formation of
the skull is a typical example of intramembranous ossiﬁcation (Fig. 3).
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Fig. 1. A and B) Lateral and anterior–posterior radiograph of the skull of a two-year-old patient with MPS VI. Note the atypical shape of the skull, (dolichocephalic) with partial
craniosynostosis involvingmainly the sagittal and the lambdoid sutures (not visible) and the thickened skull (rectangle). C) Shows an X-ray of an eight-year-old patient with MPS VI.
Note the irregularities of the epiphyses in the femoral heads. The growth plates of both femur heads are too small and lateralized (arrows). The neck of the caput femoris is broad and
plump (two headed arrow) and in a valgus position. There is dysplasia of the acetabuli (arrowheads); the right acetabulum is steep and shallow. The asterisk shows ﬂaring of the
wing of the os ileum. D) Shows an X-ray of a ten-year-old patient with MPS VI. Note the deformed and ﬂattened epiphyses of the femur (arrows), and the dysplastic acetabuli
(arrowheads). E and F) Abnormal teeth in an eight-year-old and a six-year-old patient with MPS I. Both patients have hypoplastic peg-shaped teeth (arrows) and dysplastic teeth
(arrowheads). The asterisks indicate gingival hyperplasia.
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osteoblasts, and are deposited amid very loose mesenchymal tissue.
During the process of embryonic development, the plates of bone are
continuously reshaped as they grow. Osteoblasts and osteoclasts work
in concert to obtain the proper curvature: old bone is carved away from
the inside and new bone deposited on the outside. Defects in this
process can lead to an abnormal shape of the skull, such as that seen in
pycnodysostosis, which is caused by cathepsin K deﬁciency. The
different plates of the skull fuse shortly after birth, forming an inﬂexible
bony joint called synostosis.
A role in intramembranous ossiﬁcation is played by bone-
morphogenetic proteins such as BMP2, BMP4, and BMP7. These are
thought to activate transcription factor Cbfa1 in the mesenchymal
cells, which are thus transformed into osteoblasts [25].
Rapid growth of long bones is achieved by endochondral ossiﬁcation
and requires the presence of a growth plate. The growth plates disappeartoward adulthood, when lengthwise bone growth stops, though bone
widening may still occur.
Skeletal long bones are initially deposited in themesenchymal tissue
as a cartilage template, whose shape resembles a miniature version of
the bone to be formed. When the cartilage template reaches a certain
size, a collar of bone is deposited around the mid portion, and blood
vessels penetrate the cartilage structure. Chondrocytes in the center
enlarge and die through apoptosis. Osteoprogenitor cells, which are
transported to this region by the blood vessel, differentiate into
osteoblasts and form a primary ossiﬁcation center, which later becomes
the diaphysis. Secondary ossiﬁcation centers appear later at the thicker
endings of the cartilage template. These become the epiphyses.
Until adolescence, the growth plate remains cartilage, and separates
the diaphysis from the epiphysis. Cartilage is also maintained at the
endings of the bones where joints are formed. In this area, the
mesenchymal cells that have formed the cartilage templates of opposing
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Fig. 2. The growth chart of a patient with MPS VI (open circles). Enzyme-replacement
therapy was started at 7 years of age (arrow).
Fig. 4. The epiphyseal growth plate. 1) The resting zone: hyaline cartilage with
chondrocyte progenitor cells. 2) The proliferative zone: chondrocytes undergo rapid
mitosis and align into vertical columns. The columns are separated by septa of
extracellular matrix consisting primarily of collagen (collagen type II) and pro-
teoglycans. 3) The hypertrophic zone: chondrocytes mature and become hypertrophic.
They contain large amounts of glycogen and start to secrete alkaline phosphates and
collagen type X. The matrix is reduced to thin septa between the chondrocytes. 4) The
calciﬁed cartilage zone: concurrent with the death of chondrocytes, the thin septa of
cartilage matrix are calciﬁed by the deposition of hydroxyapatite. 5) The ossiﬁcation
zone: blood capillaries and osteoprogenitor cells invade the cavities left by the
chondrocytes. The osteogenitor cells form osteoblasts, which are distributed in a layer
over the calciﬁed septa. The osteoblasts deposit young bone (osteoid) on top of the
three-dimensional calciﬁed cartilage matrix (Mescher AL 'Junqueira's Basic Histology',
Brighton et al. [24]). The bone matrix consists of collagen type I, GAGs, and inorganic
material (Ortega et al. [37]).
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a diarthrosis with free bone movement, or leaving a synarthrosis with
little or no movement, such as syndesmosis, synchondrosis or
synostosis. The cavity of a diarthrosis is ﬁlled with synovial ﬂuid
produced by the synovial membrane protruding into the joint from the
periphery. Theﬂuid provides lubrication to the joint andnutrients to the
avascular articular cartilage [16,24].
The growth plate is divided into ﬁve zones: a resting zone, a
proliferative zone, a hypertrophic zone, a calciﬁed zoneandanossiﬁcation
zone. These start at themidportionof thegrowth-plate, andextend in two
directions, with major growth taking place toward the diaphysis, and
minor growth toward the epiphysis (see Fig. 4) [16,24].
The hypertrophic chondrocytes are degraded by osteoclasts, and the
osteoblasts, arising from osteoprogenitor cells, deposit uncalciﬁed young
bone (osteoid) against the remnants of the cartilage matrix. The
mineralized bone trabeculae that are formed support the growth plate.
Many different factors are involved in endochondral ossiﬁcation.
GAGs have an important regulatory function. They interact in the
FGFs, BMPs (as described below), TGF-β, and thewingless-type (Wnt)
signaling pathways [26].
2.3. The extracellular matrix (ECM) of bone and cartilage; the role of
GAGs
Fifty percent of the extracellular bone matrix consists of inorganic
material: calcium, phosphorus, bicarbonate, citrate, magnesium, potas-
sium and sodium. Calcium and phosphorus form hydroxyapatiteFig. 3. Intramembranous ossiﬁcation: 1 and 6) mesenchyme; 2 and 4) osteoblasts; 3)
bone with osteocytes; 5) compacted mesenchyme with a blood vessel.crystals. The organic material in the matrix of bone consists of collagen
type I ﬁbers; in the cartilage, it consists of collagen type II ﬁbers. Large
water-retaining proteoglycan aggregates (PG) ﬁll the intervening
spaces, interacting with the network of collagen ﬁbers. The entire
structure of cells and extracellular matrix is completed by various
glycoproteins, such as chondronectin [16]. Homeostasis of the extra-
cellular matrix depends on the balance between de-novo synthesis and
degradation of the matrix components; for this the osteocytes and
chondrocytes have the primary responsibility [27].
In cartilage the collagen ﬁbers are organized in a lacy network that
provides tensile strength [28,29]. Aggrecan is the most common PG in
articular cartilage. Chondroitin and keratan sulfate are the side chains
of aggrecan [30]. Other smaller proteoglycans are less abundant and
have one or two GAG side chains, such as dermatan sulfate or heparan
sulfate [31].
2.4. Proteoglycans, glycosaminoglycans, and hyaluronic acid as matrix
components
Proteoglycans typically consist of a protein core to which long sugar
chains (glycosaminoglycans) are covalently attached. The attachment
sites are formed by serine residues in the core protein that occur at an
interval of 12 amino acids.
Proteoglycans have a feather-like structure (Fig. 5). The glycosami-
noglycans linked to the serine residues consist of repeating disaccharide
units of sulfated and unsulfated uronic acids, andN-acetyl hexosamines.
The composition of the repeating disaccharide units determines the
name of the glycosaminoglycans, for example heparan sulfate (HS),
dermatan sulfate (DS), chondroitin sulfate and keratan sulfate (KS). KS
does not contain uronic acid moieties, but galactose instead.
Fig. 5. Aggrecan is the complex of proteoglycans that all are connected to a central long chain of hyaluronic acid via link proteins (red dots). The proteoglycans in the large aggrecan
complex are feather-like structures composed of a number of regularly spaced glycosaminoglycan chains, such as keratin sulfate and chondroitin sulfate (in light blue), which are
covalently linked to a protein core (yellow).
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glycan side chains. The large proteoglycan structures are linked to a
polysaccharide backbone, hyaluronic acid; together, they form an even
more voluminous complex. In the extracellular matrix of articular
cartilage, the longchainofhyaluronic acid is oriented inparallelwith the
collagen type II ﬁbers.
The featherlike structure of proteoglycans overlays the collagen
ﬁbers, forming a tight molecular network. Because the negatively
charged glycosaminoglycans have a capacity to bind and retain water,
they form a jelly-like structure. The tightly packed negatively charged
glycosaminoglycans move apart as far as possible. They are brought
together by pressure; the more pressure is put on the cartilage, the
higher the repelling force will be. This enables the cartilage of the joints
to absorb shocks.
An intact proteoglycan network is essential for the integrity and
assembly of the functional cartilagematrix. Thiswasdemonstrated in an
artiﬁcial system of cultured chondrocytes [31] which showed that
inhibition of GAG incorporation in newly formed cartilage matrix not
only causes the newly synthesized GAGs to diffuse further away from
the chondrocytes, but also reduces the cross-linking of the collagen.
Proteoglycans – mainly those inserted into the plasma membrane
and containing few glycosaminoglycan side chains – also serve as key
biological response modiﬁers. Some of these roles are addressed
below. Summarized brieﬂy, they act as 1) stabilizers, cofactors, and/or
co-receptors for growth factors, cytokines, and chemokines; 2)
regulators of cathepsin activity; 3) signaling molecules during
embryogenesis and in response to cellular damage such as wounding,
infection, and tumorigenesis; and 4) targets for bacterial, viral, and
parasitic virulence factors (attachment, invasion, and immune system
evasion) [10–12].2.5. Bone remodeling and the extracellular matrix (ECM)
Bone remodeling is a continuous process of bone resorption
(osteoclasts) and bone formation (osteoblasts). The average turnover
(volume replacement) of bone is 10% per year, but there are large
differences dependent on age and bone regions [15]. Bone tissue is able
to adapt its structure and function in response tomechanical forces and
metabolic demands [32]. A change in the balance between bone
resorption (osteoclast) and bone formation (osteoblast) results in a
corresponding loss or gain of bone tissue.
As cathepsins and matrix metalloproteinases (MMPs) are key
enzymes in the turnover of the ECM, they are essential to the process
of bone remodeling [27]. Cathepsin K is highly expressed by osteoclasts.
It is a lysosomal enzyme that cleaves the triple helical region of type I
and II collagen at multiple sites [27,33].
During endochondral ossiﬁcation, cathepsin K degrades type II
collagen (cartilage) in the hypertrophic zone to create space for the
deposition of young bone by osteoblasts [34]. Some evidence has been
presented that certain types of GAGs modulate the cathepsin K activity
depending on their concentrations [35]. According to this model, GAG
storage in MPS might affect the bone remodeling [36].
Because MMPs fragment the protein core of the proteoglycans, the
extracellular matrix (ECM) disintegrates, resulting in a cascade of
events. The release of biologically active components activates other
proteases, and affects processes such as cell attachment, migration,
proliferation, differentiation and apoptosis [37].
MMP activity is controlled by various mechanisms. For instance,
MMP transcription is upregulated via growth factors and cytokines, and
MMP translation and proenzyme activation are regulated by tissue
inhibitors (TIMPs; tissue inhibitors of metalloproteinases), which
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inﬂuence proenzyme activation [38–40]. Precise regulation of MMP
activity is crucial for maintaining the balance between tissue remodel-
ing and destruction.
During endochondral ossiﬁcation, at least three MMPs are highly
expressed. When neovascularization of the cartilage anlage begins,
MT1-MMP and MMP9 are expressed in the pre-osteoclasts and other
chondroclastic cells of unknown origin. MMP13 is expressed in the
terminal hypertrophic chondrocytes and the newly recruited osteo-
blasts [37].Fig. 6. Embryonic tooth formation in rabbit. 1) ameloblast; 2) dentin; 3) odontoblast; 4)
mesenchyme.2.6. Interaction of GAGs with bone morphogenetic proteins (BMPs) and
ﬁbroblast growth factor (FGF)
Bone morphogenetic proteins (BMPs) are multi-functional growth
factors that belong to the transforming growth factor β (TGF-β)
superfamily [41]. They interact with several regulatory pathways [42]
and promote the differentiation of osteoclasts and chondrocytes from
mesenchymal progenitor cells. In the growth plate they also promote
chondrocyte hypertrophy and apoptosis. Strict regulation of the BMP
activity is required to secure normal bone formation during postnatal
life [41].
BMPs play an integral role in the development of the skeletal
system, but also of the heart and the nervous system [43]. In humans,
mutations in the BMP pathway are associated with skeletal disorders.
For instance, a mutation in the Ib BMP receptor has been identiﬁed
in a patient with brachydactyly, and mutations in the BMP antagonist
noggin have been found in patients with symphalangism and
synostoses [42].
BMPs are secretory proteins with the ability to promote bone
formation, but can also induce formation of ectopic cartilage. Although
the activities of BMPs and their antagonists are modulated by heparan
sulfate containing proteoglycans (HSPG), it is not fully understood how
their activity in the MPS storage diseases is inﬂuenced by these GAGs
[43], whose sulfated residues are thought to bind to BMPs and their
antagonists, thereby modulating receptor-mediated signaling.
The growth factor regulatory role of some of the GAGs is also shown
by a chondroitin-sulfate-synthesis-deﬁcient mouse model. Mice deﬁ-
cient for chondroitin 4-sulfotransferase have growth plate abnormal-
ities resembling those in MPS VI mice, in which the TGF-β signaling is
upregulated and the BMP signaling down-regulated, indicating that
chondroitin sulfate balances the activity and localization of these two
growth factors [44,45].
Fibroblast growth factor and BMP signaling have opposing
functions in the growth plate. They interact through mutual antago-
nism. FGF ligands and FGF receptors (FGFR) are both expressed in
developing skeletal and cartilage anlage. Several human craniosynos-
tosis disorders have been linked to activating mutations in FGF
receptors. Disruption of FGFR2 signaling in skeletal tissues results in
skeletal dwarﬁsm and lower bone-mineral density (BMD). Lower
proliferation of osteoprogenitor cells is combined with reduced
anabolic function of mature osteoblasts and diminished osteoblast
differentiation [46,47].
FGF-2, a prototypical member of the FGF family that is involved in
tissue morphogenesis and neurogenesis, binds to two kinds of cell-
surface receptors: high-afﬁnity FGF receptors (FGFRs), and low-afﬁnity
receptors (composed of HSproteoglycans) that act as extracellular FGF2
reservoirs and coreceptors. Formation of the FGF-2–FGFR–HSPG
complex is necessary for mitogenesis and optimal biologic response to
FGF-2 [48]. Dermatan sulfate (DS) also binds and activates FGF-2. The
interaction betweenDS and FGF-2 has been studied onlywith respect to
cellular proliferation: in its capacity to stimulate cell growth in vitro, DS
exceeded HS [49].
Three studies have suggested that high concentrations of small,
abnormally sulfated, HS chains (such as those present in Hurlersyndrome) can have a detrimental effect on orderly hematopoietic
stem-cell growth and differentiation [50–52].
2.7. Teeth
Teeth, too, are bony structures: their shaft consists of dentin, and the
crown protruding in the oral cavity is covered with enamel. The inner
part of teeth, the dental pulpa, is composed of loose connective tissue.
Odontoblasts are the cells that form the organic matrix of the shaft
(dentin) (Fig. 6), which consists of collagen type I, phosphoproteins,
phospholipids and proteoglycans. Newly formed, not yet calciﬁed
dentin is called pre-dentin and has its equivalent in osteoid, un-calciﬁed
young bone [16].
During tooth development, ameloblasts are aligned across the cap of
theprimitive tooth andproduce a layer of enamel,whichalso is a formof
bone. In thisway the crown is formed. The root is coveredwith a layer of
cementum produced by the cementoblasts; this is connected to the
bony socket of the jaw by the peridontal ligament, an array of collagen
ﬁbers that also holds the teeth in position [53].
2.8. Development of the teeth
The mandible and maxilla grow to accommodate the developing
teeth. The enamel on the crown of the teeth is derived from ectoderm;
all other parts differentiate from the surrounding mesenchyme. Tooth
buds of the primary dentition appear around the tenth week of
embryonic development; the buds for the second dentition start to
develop four years after birth [53].
2.9. BMPs and FGFs and their role in tooth development
GAGs can affect BMP activity as described above. BMP4 plays an
important role in tooth development from the moment the initial
epithelial lamina is formeduntil the late bell stage [54]; duringpostnatal
tooth development, it is highly expressed in both the odontoblasts and
in ameloblasts.
Initial tooth development appears to require a BMP signal. Deletion
of the BMP4 gene in odontoblasts and surrounding osteoblasts leads to
permanent defects in tooth cytodifferentiation, and also in the
supporting periodontal tissue (decreasing the rate of formation from
pre-dentin, decreasing odontoblast maturation, affecting proper den-
tinal tubule formation, and reducing the expression of collagen type I
and osteocalcin). Inmice, dysmorphogenic odontoblasts were seen that
failed to properly elongate and differentiate, thereby producing
permanently thinner dentin, enlarged pulp chambers in the molars,
and less bone tissue to support the teeth. Indirectly, deletion of the
BMP4 gene also disturbed the process of enamel formation. Postnatally,
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amelogenesis [54].
The BMP2 gene appears to be involved in BMP4 activation. Its
deletion in odontoblasts leads to disorganization of morphologically
altered odontoblasts at thedentinal tubule stage and failure tomature in
later stages of tooth development [54].
Fibroblast growth factors (FGFs) are involved in epithelial–
mesenchymal tissue interaction. FGF signaling via FGFR2 in the
epithelium is crucial for cell proliferation during tooth and palate
development [55]. Interference of abnormal HS and DS (as seen in
MPS) with the FGF pathway may cause abnormal growth and
differentiation of teeth in MPS [48,52].
3. Bone, joint and tooth problems in mucopolysaccharidoses
Although the severity of bone disease varies by the type of MPS, most
of the skeletal anomalies in MPS patients are likely to originate from
aberrant cartilage and bone development. For instance, the complex
skeletal pathologyobserved in six-week-oldMPS Imice suggests that very
early changespredispose for thedysostosis that becomesapparent later in
life [56].Growth in length relieson theperfectlyorchestratedproliferation
anddifferentiation of chondrocytes in the growthplate— a processwhich
is irreversibly disturbed in MPS by the lack of GAG turnover.
Various bone problems inMPS patients can be explained by abnormal
endochondral ossiﬁcation: they include thoracolumbarkyphosis/scoliosis,
odontoid hypoplasia, wide oar-shaped ribs, shortened long bones, coxa
valga, dysplastic femoral heads, genu valgum, and bullet-shaped
phalanges. Histological abnormalities have been reported in each of the
5zonesof thegrowthplate. Thesearedescribedbelow.Themain causesof
osteopenia in MPS patients are probably abnormal bone remodeling
(osteoblast/osteoclast dysfunction) andabnormalities in thegrowthplate,
exacerbated by immobility in an advanced stage of the disease.
Developmental deformities of the vertebral bodies and the femoral
heads accelerate the normal degeneration of the joints caused byweight-
bearing forces; they also induce inﬂammation.
Macrocephaly with thickened skull and short wide clavicles can be
explainedby abnormal intramembranous ossiﬁcation andabnormal bone
remodeling. Reports of MPS cases with craniosynostosis in the literature
have speculated that GAGs may interact with the FGF receptor [46,47].
Dental complications in mucopolysaccharidoses (MPS I, IV and VI)
can be severe. They include hypoplastic peg-shaped teethwith retarded
eruption or unerupted dentition; thin enamel (often ‘grayish’); a pitted
surface; dentigerous, cystlike follicles, malocclusions; short mandibular
rami with abnormal condyles (condylar defects); and gingival hyper-
plasia [57–59]. Affected MPS patients easily develop dental caries and
need regular conservative dental therapy [60].
Secondary cellular responses, involving interactions of GAGs with
BMP and FGF,may play a role in all bone, joint, and tooth problems seen
in MPS patients.
3.1. Endochondral ossiﬁcation and the epiphyseal growth plate in MPS
patients and animals
3.1.1. Resting zone
Chondrocytes in the resting zone of the growth plates of patients
with MPS I, II and IV are unusually large and contain granular material.
They are named “foam” cells, as they contain numerous large
cytoplasmic vacuoles ﬁlled with undegraded GAGs. Foci of loose
connective tissue interrupt the architecture of thegrowthplate, creating
irregularly shapedmetaphyses. The remaining parts of the growth plate
are fairly regular, with well-organized endochondral ossiﬁcation [61].
In a MPS VI cat model, the resting zone of the tibia occupies a larger
than usual space in which the chondrocytes are rather tightly packed
(hyperplasticity) [62]. Clonal expansion of the chondrocytes in the
resting zone, which is seen in MPS VI cats, can be explained by aresponse to GAGaccumulation. GAGs are negatively charged and able to
mobilize and bind mitotic growth factors.
Comparedwith the proliferative andhypertrophic chondrocytes, the
articular chondrocytes and the chondrocytes in the resting zone have a
long half-life. Pathology is thereforemore likely to develop in the slowly
dividing cells in the resting zone.
3.1.2. Proliferative and hypertrophic zones
In the MPS VII mice the number of chondrocytes in the proliferative
zone ismarkedly decreased (60%); the proliferative capacity is only 55%
of normal. The ECMdirectly surrounding the chondrocytes is very rich in
chondroitin-4-sulfate (C4S). On the basis of these ﬁndings it has been
hypothesized that C4S might interact with a cell membrane receptor
and thereby reduce chondrocyte proliferation and bone growth [63].
In six-week-old MPS I, mice the growth plate is abnormally broad
with distended resting, proliferative, and hypertrophic zones. The
chondrocytes are hypertrophic. In contrast to the decreased prolifera-
tion in the MPS VII mice, the proliferative zone in six-week-old MPS I
mice occupies a relatively high number of chondrocytes, and the
columnar organization is relatively well preserved. In older mice, the
columnar organization of the growth plate is disrupted, and the bone
trabeculae begin to thin [56].
Similar defects in the process of endochondral ossiﬁcation have
been observed in MPS I patients, in cats with MPS I and MPS VI, and in
mice with MPS VI [64]. For instance, chondrocyte maturation in
distinct regions of the hypertrophic zone was disorganized in the iliac
crest growth plate of MPS I patients, and in the growth plates in the
femoral head and tibia of MPS VI cats [64]. The lower rate of bone
growth in MPS patients and animal models may be attributable to
delayed turnover of hypertrophic cells [62]. The lower number of
hypertrophic cells in MPS VI rats has been ascribed to enhanced
expression of TGF-β that inhibits the terminal differentiation of
immature chondrocytes [38]. A decrease in the number of hypertro-
phic chondrocytes that are subsequently replaced by bone can explain
the osteopenia in MPS VI rats.
3.1.3. The ossiﬁcation zone
The accumulation of GAGs in MPS VII mice and dogs has been
demonstrated in osteoclasts and osteoblasts located in the ossiﬁcation
zone [65].
In the iliac growth plate of humans with MPS I there were fewer
longitudinal septa upon which cartilage mineralization and metaphy-
seal osteoblastic activity could occur. The primary spongiosum was
irregularwith poor speculation [64]. In the femoral growth plate ofMPS
VI cats, calcifying cartilage was disorganized by irregularities in the
chondro-osseous junction, and there were osteoclast deﬁcits [66].
Abnormalities in the cortical bone structure supporting thegrowthplate
have been reported in a murine MPS I model [56]: at six weeks of age,
the zone of provisional calciﬁcation and primary spongiosa was
abnormally wide, indicating either that more matrix was produced or
that it was less degraded than normal. Islands of un-ossiﬁed cartilage
persisted amidst the newly formed bone, resulting in the loss of well-
deﬁnednarrowtrabeculae. Someof theseﬁndings couldbeexplainedby
the lack of osteoclast activity, which normally degrade GAGs from the
cartilage matrix, leaving a well-ordered scaffold consisting mainly of
type II collagen ﬁbers to which the osteoblasts can adhere.
The GAG storage in MPS I appears to compromise this process.
Ossiﬁcation starts before the GAGs have been removed from thematrix,
and remnants of the cartilage anlage are retained within the newly
formed bone. This leads to abnormalities in the composition and
architecture of the growth plate, and thus to growth retardation. The
abnormalities persist, which suggests that the lack of GAG degradation
also affects the process of bone remodeling [56].
In a MPS VI cat model the abnormalities are not restricted to the
cartilage of the growth plate but also pertain to osteoblast function,
suggesting that bone formation is deﬁcient [62]. Osteonectin, a
Fig. 7. Hallux valgus of the left foot of a 12 year old MPS II patient. Notify the redness of
the skin over the joint between the metatarsal bone and the proximal phalanx, which is
caused by inﬂammation (arrow).
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promotingbonemineralization, has beenmentioned in this context. It is
a substrate for MMP-2 and 9 that are both elevated in MPS bones and
joints [38].
Like the osteoblasts, but to an even greater extent, the osteoclasts in
MPS VII mice contain large foamy vacuoles [20]. The osteoclasts fail to
form rufﬂed border membranes and seem to detach easily from the
bone surface. These defects are intrinsic to the MPS VII osteoclasts and
not the result of an abnormal bone matrix. They are corrected during
bone-marrow transplantation, when the osteoclasts are replaced.
Osteoclast functionmay also be impaired by an excess of GAGs in the
extracellular matrix, which inhibits cathepsin K activity and thereby
cartilage resorption [35].
3.2. The role of signal transducers and activator of transcription (STAT)
Several studies have indicated the role of STAT in the process of
endochondral ossiﬁcation and MPS-related change. STAT stands for a
family of transcription factors. The phosphorylation and activation of
STAT1 by activated FGFR3 increases the expression of the cell-cycle
inhibitor p21, reducing chondrocyte proliferation [46].Metcalf et al. [63]
have shown that mRNAs that encode several of the STAT transcription
factors known to be selectively altered by inﬂammation were
abnormally expressed in the growth plates of MPS VII mice.
3.3. Osteopenia and osteoporosis in MPS
The abnormal cartilaginous structures in the epiphyseal growth
plate are an important cause of osteopenia inmostMPSpatients, but not
in MPS III patients. Heparan sulfate accumulation causes neurological
complications (psycho-motor retardation) and only minor skeletal
abnormalities including coarse facies and joint stiffness [67].
The psycho-motor retardation in MPS I, II and III might also
contribute to osteopenia or osteoporosis. The secondary inducers
include immobilization, too little exposure to the sun, poor nutritional
status, vitaminD deﬁciencies and treatmentwith anti-epileptica [68]. In
MPS IV and VI patients, severe bone deformities (immobilization) and
vitamin D deﬁciencies are also described [69].
3.4. The role of weight-bearing forces on abnormally shaped bones and
joints
In MPS patients, abnormal bone structures (dysostosis multiplex)
are seen very early in life. The acetabula of the hips inMPS I, II, IV and VI
patients are short and steep and form an abnormal acetabular cup. The
morphology of the femoral head and neck can be changed not only by
accumulation of GAGs in the growth plate and bone cells, but also by
abnormal weight-bearing forces. The latter is shown in Fig. 7, which
demonstrates hallux valgus in a patient with MPS II. Hallux valgus is an
abnormal angulation of the big toe involving the joint between the
metatarsal bone and the proximal phalanx. It also occurs in the normal
population (Fig. 8). The wrongly directed pressure on the bones can
cause joint inﬂammation, affect the GAG content of the articular
cartilage, and induce secondary alterations in the underlying bone. It
also has a long-range effect on the cartilage structure of the joint
between the proximal and distal phalanges. The proximal site of the
joint between the metatarsal bone and the proximal phalanx has fully
disappeared due to the inﬂammation. The distal site of this joint has a
very low GAG content, although the gross structure is still preserved. In
response to the primary pathologic changes, new bone is formed at the
periphery of the joint (osteophyt); and immature cartilage and bone are
formed justunder the zoneof articular cartilage. BMPs andother growth
factors are likely involved in these processes. Although not directly
involved, the cartilage of the joint between the proximal and distal
phalange of this toe also has a very low GAG content. Thus, in this
pathological condition mixed aspects of osteo arthritis and rheumatoidarthritis (OA and RA) are seen, which also occur in MPS. Recently Baldo
et al. described this phenomena in a knee joint of anMPS Imurinemodel
[70] showing inﬂammatory inﬁltration and pannus formation with
hypertrophy of synovial cells.
Although the primary causes of hallux valgus in the general
population and in MPS patients are totally different, the cascade of
pathologic events and the consequences are partly similar.3.5. Joints and inﬂammation
Simonaro et al. hypothesized that lysosomal and/or extracellular
GAG storage in the MPS disorders induce inﬂammation and affect the
growth of connective tissue cells and other cell types by activating the
Toll-like receptor 4 (TLR4) signaling pathway [71]. Activation of this
pathway can be induced either by 1) GAG fragments interacting with
CD44, a hyaluronan-binding cell surfaceglycoprotein receptor (55 kDa),
and myeloid differentiation factor-88 (MyD88); or 2) through lipo-
polysaccharide (LPS), which requires MyD88, lipopolysaccharide
binding protein LBP, and CD14 [72–76]. Simonaro et al. have shown
that the expression of MyD88, LBP, and CD14 is up-regulated in MPS
connective tissue cells [71].
Large fragments of hyaluronic acid and oligosaccharides released by
the breakdown of the extracellular matrix also signal through TLR4 via
MyD88 and CD44, providing further support for the concept that this
pathway is activated by GAG storage in the MPS disorders [73].
TLR4 activation in MPS animals resulted in the production of
ceramide, a pro-apoptotic lipid and the release of numerous inﬂamma-
tory cytokines and proteases [77]. Among the cytokines, TNF-α was
markedly elevated both in the circulation and within the joint tissue of
MPS animals [71].
There is great similarity in the secretion of pro-inﬂammatory
cytokines like TNF-α, IL-1β and nitric oxide in the extracellular matrix
of cartilage and bone of animals and humans with primary MPS
syndromes compared with primary degenerative and inﬂammatory
process like osteo- or rheumatoid arthritis. The cytokines are produced
by MPS chondrocytes, synoviocytes, and macrophages [38].
Stimulation of MPS connective tissue cells by the inﬂammatory
cytokines causes enhanced secretion of several of the matrix metallo-
proteinases (MMPs). Dramatically elevated expression of MMP-2 and
MMP-9 and abnormally high expression of TIMP-1 accompany joint
disease in MPS [38]. The imbalance of MMPs over tissue inhibitors of
Fig. 8. Microscopic image of an amputated great toe of a 52 year old woman not affected by MPS (hallux valgus). A) Overview. B and C) show details of the joint between the
metatarsal bone and the proximal phalanx, and D) shows a detail of the joint between the proximal phalanx and the distal phalanx. The joint between the metatarsal bone and the
proximal phalanx has been destroyed by inﬂammation due to the abnormal pressure, and the GAG content in the cartilage has diminished (asterisk) (B). Also visible in this joint are
the secondary alterations in the underlying bone; in this case abnormal cartilage formation (arrows) (C). Although the gross architecture is still preserved, the cartilage of the joint
between the proximal phalanx and the distal phalanx has a very low GAG content (asterisks) (D). Image E shows healthy cartilage with normal GAG content (asterisk).
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as well as rheumatoid arthritis in joints of MPS patients.
Patients without MPS but with osteo arthritis (OA) and cartilage
degeneration have changes in the structure and composition of the
extracellular matrix, characterized by lower proteoglycan content and
enhanced collagen degradation [78]. To compensate for the loss of
matrix substance, the rate of synthesis of both matrix components is
increased [79,80].
3.6. Dental problems
Guven et al. have investigated the ultrastructural and chemical
properties of MPS I (Hurler) teeth. The dentin of the primary teeth was
characterized by extremely narrow dentinal tubules with an irregular
wave-like pattern. The enamel-dentin junction was poorly shaped,microgaps occurred and theenamel displayed an irregular arrangement
of prisms. Both the enamel and the dentin had an abnormal protein
structure and the dentin protein content was low [57].
4. Secondary cellular effects and responses in MPS
4.1. Interaction of GAGs with BMPs and FGFs
Impaired BMP-4 signaling by GAGs in multipotent adult progenitor
cells (MAPCs) in the human Hurler syndrome identiﬁes a mechanism
that might contribute to the progressive skeletal abnormalities. The
same mechanisms may be involved in development of neurological
problems [43].
It has been demonstrated that cell and matrix associated GAGs
promote proliferation and block BMP-4-mediated differentiation of
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cells may have the same effect. GAGs impair the BMP-4 activity but do
not change the expression of various BMPs or their receptors. The
activity of BMP-4 can be restored by clearing the lysosomal GAG
storage with exogenously supplied enzyme as demonstrated in
cultured cells.
Both heparan sulfate (HS) and dermatan sulfate (DS) accumulate
in Hurler syndrome and both are cleared by treatment with α-L-
iduronidase, the role of DS cannot be ruled out as a contributor to
impaired BMP-4 signaling [43] as observed in Hurler MAPCs.
HS in Hurler syndrome is structurally and functionally abnormal
and has impaired ability to bind to and mediate the effects of
ﬁbroblast growth factor-2 (FGF-2) signaling [48]. This results in FGF-
2-induced proliferation and survival of Hurler multipotent progenitor
cells. Both the mitogenic and survival-promoting activities of FGF-2
were restored by substitution of Hurler HS by normal HS. Chondroitin
4-sulfate (C4S), one of the GAGs that store in MPS VII, can activate FGF
signaling as well through some of the FGFRs [81].
4.2. Autophagy, polyubiquitination and mitochondrial function
The molecular pathways underlying pathology in lysosomal
storage diseases (LSDs) are largely unknown [82]. Recycling of the
building blocks of cells, organelles, (glycol)proteins, (glycol)lipids,
carbohydrates, and other kind of macromolecular compounds is
required for cellular homeostasis [83].
The ubiquitin–proteasome proteolytic system and the autophago-
some to lysosome pathways are both used for large scale degradation of
cellular components. The ubiquitin–proteasome system degrades short
lived regulatory proteins that are for instance important for processes
like cell-cycle progression, regulation of gene transcription and signal
transduction [84]. The long-lived structures are mainly targeted to the
lysosomes by autophagosomes [85].
Lysosomal storage leads to reduced functionality of the lysosomal
compartment and consequently leads to build-up in the autophago-
cytic and endocytic pathways [86–88]. Dysfunction of autophagy as
secondary event seems to play an important role in the pathophys-
iology of LSDs. It has been shown that lysosomal storage induces
impaired autophagy. A recent study also showed mitochondrial
dysfunction and inﬂammation to occur as secondary event in MPS
VI [83]. Similar anomalies in associationwith dermatan sulfate storage
have been observed in the visceral organs but not in the central
nervous system of MPS VI rats accompanied by inﬂammation and cell
death. Prevention of dermatan sulfate storage in these rats by gene
therapy resulted in restoration of autophagy, as well as regression of
inﬂammation and apoptosis.
4.3. Compromised lysosome membrane integrity
Compromised lysosomal membrane integrity is another problem
resulting from the accumulation of undegraded or partially degraded
substrates in the lysosomesof LSDpatients [89,90]. By leading to leakage
of ions and metabolites from the lysosomes to the cytosol, it causes
alterations in cellular homeostasis.
Pereira et al. have shown that secondary alterations, such as changes
in the Ca2+ and H+ homeostasis caused by lysosomal membrane
permeability, can contribute to cell death and to the pathophysiology of
MPS I mice [90]. For example, too high a calcium concentration in the
cytosol compromises the fusion between endosomes and lysosomes.
Too high an endosomal and lysosomal pH has a similar detrimental
effect [91], as has also been demonstrated inMucolipidosis type IV [92].
Large changes in lysosomal membrane integrity cause leakage of
lysosomal enzymes and other macro-molecules from the lysosomes in
the cytosol, where the presence of lysosomal proteases such as
cathepsins may contribute to apoptotic cell death [89,93–96].5. Relevance to therapeutic options
The following section describes the existing and potential therapeu-
tic options for preventing or correcting short stature, osteopenia, joint
stiffness and contractures in MPS patients.
5.1. Enzyme-replacement therapy
Enzyme-replacement therapy (ERT) is currently available for MPS I,
II and VI [97]. So far, although ERT ameliorates bone and/or joint
problems in MPS animal models if started very early, it has achieved
little improvement of bone disease in humans [77]. In a catwithMPS VI,
Auclair et al. injected the enzyme directly into the joint rather than
intravenously [98] to improve the therapeutic efﬁcacy in joints. This
signiﬁcantly reduced storagematerial in the articular chondrocytes and
the synovial membrane. Within two months of treatment, GAG
accumulation recurred [98]. Monthly injections had better effects than
injections every three months. The method of intra-articular therapy is
presently being tested in two MPS VI patients [99]. However, the
correction of MPS storage in the articular cartilage and the growth plate
remains challenging because the accessibility of the chondrocytes is
restricted mechanistically by slow diffusion of the relatively large
therapeutic enzymes through the molecular structure of the matrix.
With regard to age-related effects, McGill et al. reported a sibling
study in which one sibling with MPS VI started ERT in the eighth week
after birth and the other at 3.6 years. Therapeutic efﬁcacy was assessed
by comparing the two siblings' bone and joint problems. Although the
child who had been treated very young preserved joint movement, did
not develop scoliosis, and had no facial dysmorphy [100], the growth
rate of both siblingswas similarly decreased, andmacrocephalywas not
prevented in the period between birth and 3.6 years. In both siblings,
radiological changes of the skeleton progressed, and degenerative
changes took place in the joints [100].
Likewise, in the MPS VI cat model the best response occurred if
therapy started directly after birth and if antibody development was
prevented [101]. It seems that bones and joints respond better to ERT
when the treatment is started early. Neonatal screening forMPSenzyme
deﬁciencies might thus be an option for diagnosing MPS children as
early as possible [102].
5.2. Bone-marrow transplantation and hematopoietic stem-cell
transplantation
Although bone-marrow transplantation (BMT) or hematopoietic
stem-cell transplantation (HSCT) in MPS I (ideally before 18 months of
age) leads to several positive changes, it does not greatly reduce the
skeletal abnormalities [103]. If nomatcheddonor is available, cordblood
from unrelated individuals can be used for transplantation [104].
However, despite early transplantation, transplanted children often
require major orthopedic surgery for genu valgum, acetabular hip
dysplasia and kyphoscoliosis later in life [103,105,106].
In MPS animal models, osteoblast and osteoclast function was
restored by bone-marrow transplantation [20].
5.3. Gene therapy in MPS animals
Mango et al. examined the effect of liver-targeted retroviral gene
therapy in β-glucuronidase (GUSB) deﬁcient MPS VII mice and dogs. In
mice, full correction of the femur length was not obtained, despite high
level enzyme expression from the liver, not even if gene therapy was
used in very young animals. Thiswas explained by the poor accessibility
of the growth plate [65].
As an alternative to ERT and BMT/HSCT, Byers et al. examined the
effect of direct transduction of the synovial membrane of rats with a
GUSB containing lentiviral vector [107]. The transduction was only
partially successful: enzyme expression was obtained in the synovia for
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not transduced. Thiswasprobablydue to steric exclusionof viral particles
by cartilage ECM. In theory, the treatment can only work if enough
enzyme is produced by the synovial cells, which can then leak into the
synovial ﬂuid and reach the chondrocytes by diffusion through the ECM.
5.4. Short stature and growth hormone (GH)
Even though they did not have a growth-hormone deﬁciency, a
number of MPS IV patients have been given growth hormone. There
was no evidence that this improved their growth [60]. Eight children
with MPS I-Hurler syndrome who had previously undergone HSCT
also received GH treatment [108,109]; some of them had HSCT-
induced GH deﬁciency, others did not, but all had growth failure. After
one year of treatment with GH their growth failure was partially
corrected. Potential complications of GH are Legg–Calvé–Perthes
disease, scoliosis and carpal tunnel syndrome [110,111]. Although
none of the transplanted patients had to discontinue GH treatment
due to progressive scoliosis, one had a slipped capital femoral
epiphysis, which can be caused by the GH therapy.
The orthopedic complications characteristic of MPS I (Hurler) can be
exacerbated by GH treatment, though opinions differ with regard to the
prevalence and progression of scoliosis or kyphosis duringGH treatment.
Some studies have indicated that the percentage and rate of progression
of the scoliosis curve is generally higher than expected during GH
therapy; others have reported little to no progression [112–115].
Hip abnormalities with a Perthes-like disease aspect (femoral head
dysplasia, see Fig. 1A) are common in untreated MPS patients and in
patients treatedwith ERT [116]. It is not knownwhetherGHaggravates
this problem, but it can be envisaged that the growth plate becomes
disorganized when chondroblast proliferation is randomly stimulated
by GH.
The occurrence of pubertal delay in MPS VI patients and precocious
puberty inMPS III patientsmaybothbe related toprimary abnormalities
of thehypothalamic–pituitary–gonadal/thyroid hormoneaxes, andmay
potentially affect growth. However, gonadal and thyroid hormonal
dysfunctions have seldom been demonstrated in MPS patients and
argue against the existence of any substantial abnormalities of the
hypothalamic–pituitary–gonadal/thyroid hormone axes [117,118].
5.5. Osteopenia and the use of growth hormone
Throughout human life, growth hormone (GH) and insulin-like
growth factor-I (IGF-I) play important roles in the homeostasis of
bone. GH acts directly on the target tissues, i.e. bone, skeletal muscle
and many others tissues. Many of the effects of GH are indirectly
mediated by circulating (liver-derived) or locally produced IGF-I.
Although GH treatment improves osteopenia in pediatric patients
with growth hormone deﬁciency [119], the question is whether it also
improves the osteopenia in MPS patients [120].
In a GH deﬁcient rat model it was demonstrated that GH
administration increases periosteal and endocortical bone formation.
GH also mitigates trabecular bone loss by increasing bone formation
[119]. Since trabecular bone loss has been demonstrated in most MPS
animal models, there is good reason to investigate the effect of GH
dosing in MPS patients, particularly in younger ones whose bone
abnormalities and growth retardation are still limited.
5.5.1. Osteopenia and the use of parathyroid hormone
Parathyroid hormone (PTH) is best known for releasing calcium from
bone; primary hyperparathyroidism causes bone resorption. Parathyroid
hormone also has anabolic activity [121]. The anabolic properties of PTH
manifest at a low, intermittent dose. Under this regimen, PTH positively
affects bone volume and microarchitecture by stimulating bone forma-
tion. This effect was seen in postmenopausal women with osteoporosis
and in young women with growth disturbances [121,122].In the GH-deﬁcient rat model (created by hypophysectomy), PTH
increases bone formation mainly by reducing the osteoclast density
per bone area, but has hardly any effect on growth in length [119].
Given that PTH lowers osteoclast density, it would be unlikely to
have a positive effect on osteopenia in MPS patients. Given that PTH
lowers osteoclast density, it would be unlikely to have a positive effect
on osteopenia in MPS patients, since the number of osteoclasts can be
low (MPS VI cats) and their function defective (MPS VII mice) [66].
5.5.2. Osteopenia and the use of bisphosphonates
Patients with Gaucher disease (GD), a lysosomal glycolipidosis, may
also have severe osteopenia, even when treated with ERT. In Gaucher
disease this has been attributed to “chronic macrophage activation”,
inﬂammation and induction of accelerated bone turnover [103]. Bone-
mineral densitywas improvedby the administrationof bisphosphonates,
whose effect is attributed to the inhibition of osteoclast function [123].
Another lysosomale storage disorder characterized by substantial
bone abnormalities is Mucolipidosis. Patients with type III Mucolipidosis
(ML III, pseudo-Hurler polydystrophy), have skeletal manifestations
resembling thoseofMPSpatients. Theyhaveadistinctively high turnover
of bone [124] caused by vigorous, osteoclast-driven, subperiosteal bone
resorption pertaining to almost the entire periosteal surface. ML III
patients treatedwith bisphosphonates have a dramatic clinical response,
their pain decreasing and their mobility improving. Their bone density
also increased, particularly in the metaphyseal regions.
Due to immobilization, children with psycho-motor retardation
related to causes other than MPS may have severe osteoporosis. In our
clinic, suchpatients are treated successfullywith bisphosphonates. Ifwe
take these facts into consideration, it couldbe thatMPSpatients, too,will
beneﬁt from bisphosphonates. On the other hand, bisphosphonate
inhibits osteoclast function, which seems already compromised in MPS
[66].
5.5.3. Osteopenia and the use of BMPs
It hasbeendemonstrated that BMP-2 canbeused to treat osteoporosis
[41]. BMP-2 can accelerate bone healing in animal models [125] and in
humans promote intervertebral and lumbar posterolateral fusions [126].
It has also been shown to induce new dentine formation, to have a
potential application in root canal surgery, and to be an effective bone
inducer around dental implants for periodontal reconstruction [127].
Because of the stimulating effect of BMPs on osteoblast differentia-
tion, their potential application in MPS deserves attention (this review).
5.5.4. Osteopenia and exercise
The bone and joint problems in hips and knees cause pain and
restricted mobility, leading indirectly to osteopenia. Physical exercise
improves bone mass in growing children. Although the precise
mechanism whereby it inﬂuences bone metabolism is not known, a
response to greater mechanical stress and to changes in endocrine
parameters are both likely contributors [32]. Physiotherapy andexercise
might therefore improve osteopenia in MPS patients.
5.6. Intervention at the level of secondary cellular events
As stated above, various secondary effects occur in the pathophy-
siolgy of MPS, including disturbed autophagy and polyubiquitination,
mitochondrial dysfunction, inﬂammation, apoptosis, and loss of
lysosomal membrane integrity. These secondary events can be
prevented or resolved by reducing the lysosomal storage of GAGs.
While this can be achieved by ERT or gene therapy [20,35,83,128], the
lysosomal GAG load can also be limited by reducing GAG synthesis.
Such substrate reduction is used in Gaucher disease and Niemann Pick
disease type C [97]. Used as a substrate inhibitor in MPS III animal
models, Rhodamine B has beneﬁcially affected CNS function [97].
However, the effect of substrate inhibition on bone problems in this
and other MPSs has not yet been demonstrated.
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Research has been done on preventing the damage of bones and
cartilage, which is caused by inﬂammation. Simonaro et al. showed
the important role of TLR4 signaling in MPS bone and joint disease,
and suggested that targeting TNF-α may have positive therapeutic
effects [77].
6. Concluding remarks
Growth retardation, dysostosis multiplex, osteopenia/osteoporo-
sis, stiff joints and abnormal teeth in MPS patients are the ﬁnal result
of lysosomal GAG accumulation in connective-tissue-forming cells
such as mesenchymal cells, ﬁbroblasts, chondrocytes, osteoblasts and
osteocytes, osteoclasts, odontoblasts, ameloblasts and cementoblasts.
The primary cause of cellular dysfunction is intralysosomal GAG
storage, which directly affects the composition and metabolism of the
extra-cellular matrix. These primary events evoke a cascade of
pathological processes that have local effects on tissue and organ
function, and distant effects on systemic functions. As the MPS-
degrading enzyme deﬁciencies are determined genetically, the GAG
storage starts in utero, eliciting a long-term effect on body structure
and function. Skeletal malformations, dental dysplasia and hypoplasia
are all pre-eminent examples of this process. To conclude this review,
Fig. 9 summarizes the cascade of pathologic events, starting with
primary GAG storage.
6.1. Primary and secondary cellular events
GAGs, one of themajor components of the extracellular matrix, are
synthesized and recycled by the connective tissue cells. They enter the
cell by endocytosis and are degraded in the lysosomes. If one of the
lysosomal enzymes involved in their degradation is missing or
malfunctioning because of a genetic defect, GAGs accumulate in
lysosomes. Intra-lysosomal GAG storage not only expands the volume
of the lysosomal system, but also the functioning of the lysosomes as
end-stations of the endocytic and autophagocytic transport pathways.Fig. 9. Pathologic cascade in mucopolysaccharidoses. 1) Lysosomal GAG storage due to deﬁc
3) Impairment of endosome–lysosome fusion, affecting remodeling of the extra-cellula
homeostasis. 5) Leakage of lysosomal hydrolases and H+ out of the lysosome elevates the
proteases into the cytosol may contribute to apoptosis. 7) Elevated Ca2+ levels in the cyt
pathway by GAGs leads to the production of ceramide, which in turn leads to the release
imbalance of MMP-2/9 and TIMP-1 causes degradation of the ECM. 10) Certain GAGs can mThe lysosomalmembrane integrity is compromised, which has several
consequences, such as dysfunction of the lysosomal membrane
ATPase proton pump and leakage of proteases (cathepsins) into the
cytosol. The high intra-lysosomal pH prohibits optimal functioning of
lysosomal hydrolases, thereby contributing to secondary lysosomal
storage. The release of lysosomal cathepsins and other lysosomal
proteases into the cytoplasm has been associated with apoptosis.
Dysfunction of autophagy leads to a series of cellular disturbances,
including mitochondrial dysfunction. Abnormal vesicular trafﬁc also
affects endocytosis and thereby remodeling of the extra-cellular
matrix. Such remodeling is also affected by the excess of proteogly-
can, which can inhibit or stimulate cathepsin K activity.
Most of the secondary cellular events are not unique for MPS, but
occur in several of the lysosomal storage disorders. A review of the
pathological cascade in neuropathic lysosomal storage disorders has
recently beenpublished and it shows several similaritieswith themodel
presented here for the MPS [129].
6.2. Cell-type-speciﬁc and tissue-speciﬁc events
Lysosomal GAG storage in chondrocytes directly affects the growth
and maintenance of cartilage. In early life, long bones grow by
endochondral ossiﬁcation; a disturbance of this process by chondrocyte
malfunction leads to poor growth, skeletal malformations and also
osteopenia, whereby fewer trabeculae are formed and less calciﬁcation
takes place. Articular cartilage of the joints persists throughout life. The
GAG storage in this tissue culminates in a pathology resembling osteo
arthritis, as well as rheumatoid arthritis.
GAG storage in osteoblasts, osteocytes and osteoclasts hampers
adequate bone formation and bone remodeling. Early anatomical
abnormalities of bones can induce and enhance osteo arthritis and
inﬂammation, such as that caused by abnormal weight-bearing forces.
Inﬂammation itself is detrimental to chondrocyte function, as it leads to
loss of extracellular matrix components (as in hallux valgus).
Lysosomal storage of GAGs in teeth-forming cells such as the
odontoblasts, ameloblasts and cementoblasts seems to be the greatest
cause of abnormally shaped and irregularly positioned dental elements.iencies of MPS-degrading enzyme. 2) Impairment of autophagosome–lysosome fusion.
r matrix. 4) Compromised lysosomal membrane integrity and disturbances of ion
lysosomal pH and diminishes lysosomal function. 6) Leakage of cathepsins and other
osol, compromises the fusion of endosomes and lysosomes. 8) Activation of the TLR4
of cytokines and proteases, which further elevates the TNFα level. 9) GAG-induced
odulate the cathepsin K activity, which might affect ECM remodeling.
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and bony elements of the mandibula and maxilla, GAG storage in the
osteocytes probably contributes to the problem.
6.3. Secondary responses
Partially degraded and undegraded GAGs interact with several
growth factors, such as BMPs, FGFs and the FGF receptor. Activation of
the TLR4 signaling pathway has been demonstrated in osteoblasts,
osteocytes, osteoclasts, chondrocytes and odontoblasts and in the ECM
in association with inﬂammation.
Elevated expression of metalloproteinases and unbalanced elevation
of metalloproteinase inhibitors causes osteo arthritis and rheumatoid
arthritis, cumulating inarticular cartilagedegeneration. Theproteoglycan
content of the ECM is low and the collagen is degraded abnormally fast.
6.4. Primary and secondary interventions
Therapeutic interventions reducing the lysosomal GAG storage are
also expected to resolve some of the secondary pathophysiologic events.
While enzyme-replacement therapy seems the ﬁrst logical option, its
effect on bone, joint and toothpathology is limited by the texture of these
tissues. Cartilage is a-vascular, and large molecules can barely diffuse
through the matrix. Bone cells are nourished by short connections with
the blood vessels, but bone has a very slow turnover. In addition, the
bone, joint and tooth problems are the result of long-term aberrant
formation and maintenance of these tissues, which makes the abnor-
malities largely irreversible. Very early intervention is therefore
mandatory. Surgical intervention can correct or minimize some of the
joint, bone and dental problems at a later age. Standard approaches can
help to resolve inﬂammation related morbidity.
Growing insight in the cascade of pathophysiologic events is
slowly but steadily opening the doors that will enable us to improve
the lives of MPS patients by manipulating the disease process at the
primary or secondary levels.
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